Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Dopamine agonists (DA) and somatostatin (SS) analogues have been proposed in the treatment of ACTH-producing neuro-endocrine tumours that cause Cushing's syndrome. Inversely, glucocorticoids (GCs) can differentially influence DA receptor D 2 or SS receptor subtype (sst) expression in rodent models. If this also occurs in human neuro-endocrine cells, then cortisol-lowering therapy could directly affect the expression of these target receptors. In this study, we investigated the effects of the GC dexamethasone (DEX) on D 2 and sst expression in three human neuro-endocrine cell lines: BON (carcinoid) and TT (medullary thyroid carcinoma) versus DMS (small cell lung cancer), which is severely GC resistant. In BON and TT, sst 2 mRNA was strongly down-regulated in a dose-dependent manner (IC 50 0.84 nM and 0.16 nM), whereas sst 5 and especially D 2 were much more resistant to DEX treatment. Sst 2 down-regulation was abrogated by a GC receptor antagonist and reversible in time upon GC withdrawal. At the protein level, DEX also induced a decrease in the total number of SS (−52%) and sst 2-specific (−42%) binding sites. Pretreatment with DEX abrogated calcitonin inhibition by sst 2-preferring analogue octreotide in TT. In DMS, DEX did not cause significant changes in the expression of these receptor subtypes. In conclusion, we show that GCs selectively down-regulate sst 2, but not D 2 and only to a minor degree sst 5 in human neuro-endocrine BON and TT cells. This mechanism may also be responsible for the low expression of sst 2 in corticotroph adenomas and underwrite the current interest in sst 5 and D 2 as possible therapeutic targets for a medical treatment of Cushing's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dopamine receptors: from structure to function
MISSALE, C., NASH, S. R., ROBINSON, S. W., JABER, M., & CARON, M. G. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.1.189 · Cited by 3,633
Dopamine Receptor Expression and Function in Corticotroph Ectopic Tumors
Pivonello, R., Ferone, D., de Herder, W. W., Faggiano, A., Bodei, L., de Krijger, R. R., Lombardi, G., Colao, A., Lamberts, S. W. J., & Hofland, L. J. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0728 · Cited by 68 · cited 1×
“The use of sst2- or D2-targeting agonists has also been advocated in cases of Cushing’s syndrome due to ectopic ACTH production by neuro-endocrine tumours (von Werder et al. 1996, Pivonello et al. 2007).”
BackgroundSelf-citationRole of glucocorticoids in dopamine-related neuropsychiatric disorders
Craenenbroeck, K. V., Bosscher, K. D., Berghe, W. V., Vanhoenacker, P., & Haegeman, G. (2005) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2005.10.007 · Cited by 64
Cited by
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Young, J., Haissaguerre, M., Viera-Pinto, O., Chabre, O., Baudin, E., & Tabarin, A. (2020) · European Journal of Endocrinology · doi:10.1530/eje-19-0877 · Cited by 232
Cushing's syndrome: epidemiology and developments in disease management
Feelders, R., Sharma, S., & Nieman, L. (2015) · Clinical Epidemiology · doi:10.2147/clep.s44336 · Cited by 210
Self-citationRaff, H., Sharma, S. T., & Nieman, L. K. (2014) · Comprehensive Physiology · doi:10.1002/cphy.c130035 · Cited by 141
“In vitro studies have shown that glucocorticoids selectively downregulate sst 2 , and to a lesser degree sst 5 , receptor expression in human neuroendocrine cells (47, 193).”
Metadata
- Authors
- de Bruin, C., Feelders, R. A., Waaijers, A. M., van Koetsveld, P. M., Sprij-Mooij, D. M., Lamberts, S. W. J., & Hofland, L. J.
- Venue
- Journal of Molecular Endocrinology
- Publisher
- Bioscientifica
- Published
- 2008-10-13
- Volume
- 42
- Issue
- 1
- Pages
- 47-56
- ISSN
- 0952-5041 (ISSN-L)
- 1479-6813
- OpenAlex
- W2157658204
- Cited by
- 86
- References
- 3
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. https://app.cochat.ai/papers/10.1677/jme-08-0110
- The paper
- de Bruin, C., Feelders, R. A., Waaijers, A. M., van Koetsveld, P. M., Sprij-Mooij, D. M., Lamberts, S. W. J., & Hofland, L. J. (2009). Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro. Journal of Molecular Endocrinology. https://doi.org/10.1677/jme-08-0110
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.